摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氟-6-甲氧基苯胺 | 446-61-7

中文名称
2-氟-6-甲氧基苯胺
中文别名
2-氨基-3-氟苯甲醚
英文名称
2-fluoro-6-methoxyaniline
英文别名
——
2-氟-6-甲氧基苯胺化学式
CAS
446-61-7
化学式
C7H8FNO
mdl
MFCD03788538
分子量
141.145
InChiKey
VHHKZASLPJMWJI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    208 °C(Press: 756 Torr)
  • 密度:
    1.176±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.142
  • 拓扑面积:
    35.2
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    Xi
  • 海关编码:
    2922299090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:5bfbb45e19acece0896bbf2812dae9f0
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Fluoro-6-methoxyaniline
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Fluoro-6-methoxyaniline
CAS number: 446-61-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H8FNO
Molecular weight: 141.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Hodgson; Nixon, Journal of the Chemical Society, 1931, p. 981
    摘要:
    DOI:
  • 作为产物:
    描述:
    3-甲氧基-2-硝基苯甲酰氯 在 palladium on activated charcoal 盐酸sodium hydroxide 、 sodium azide 、 sodium hexafluoroantimonate 、 氢气silica gel 、 sodium nitrite 作用下, 以 乙酸乙酯 为溶剂, 反应 1.0h, 生成 2-氟-6-甲氧基苯胺
    参考文献:
    名称:
    一系列与4-苯基咪唑连接的苯基脲的结构活性关系。具有抗动脉粥样硬化活性的酰基辅酶A:胆固醇O-酰基转移酶的新型有效抑制剂。2。
    摘要:
    在我们的持续搜索中,以发现比N- [2-(二甲基氨基)-6- [3-(5-甲基-4-苯基-1H)]具有更强的抗动脉粥样硬化作用的系统可生物利用的ACAT(酰基-CoA:胆固醇O-酰基转移酶)抑制剂合成了一系列与4-苯基咪唑连接的苯基脲,合成了-imidazol-1-yl] propoxy] phenyl] -N'-pentylurea(3),并评估了其对主动脉和肠道ACAT的体外抑制活性以及体内降胆固醇药活动。通过策略性修饰3分子中的五个区域,即通过引入官能团或将碳原子交换为杂原子,研究了结构-活性关系(SAR)。SAR研究使我们能够在五个区域中选择最佳取代基,如下所示。(1)二甲氨基可转化为硝基,甲基,乙基,丙基,异丙基和氯。在初步的药代动力学研究的基础上,选择了苯脲邻位的甲基。(2)丁基,戊基,异戊基和新戊基是脲部分中较好的取代基。(3)丙氧基是桥连部分的最佳部分。(4)质子,甲基,乙
    DOI:
    10.1021/jm00063a014
点击查看最新优质反应信息

文献信息

  • SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    申请人:Signal Pharmaceutical LLC
    公开号:US20140200206A1
    公开(公告)日:2014-07-17
    Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R 1 , R 2 , R 3 , and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.
    本文提供具有以下结构的吡咯嘧啶化合物: 其中R1、R2、R3和L如本文所定义,包含有效量吡咯嘧啶化合物的组合物,以及治疗或预防乳腺癌,更具体地是三阴性乳腺癌的方法,包括向需要的受试者施用有效量的这种吡咯嘧啶化合物。
  • [EN] 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS<br/>[FR] DÉRIVÉS D'AZÉTIDINE OU DE CYCLOBUTANE 1,3-DISUBSTITUÉS UTILISÉS COMME INHIBITEURS DE LA PROSTAGLANDINE D SYNTHASE HÉMATOPOÏÉTIQUE (H-PGDS)
    申请人:GLAXOSMITHKLINE IP DEV LTD
    公开号:WO2018069863A1
    公开(公告)日:2018-04-19
    A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    式(I)的化合物,其中R、R1、R2、R3、Y、Y1、a、X和Z的定义如本文所述。本发明的化合物是造血前列腺素D合成酶(H-PGDS)的抑制剂,可用于治疗杜兴氏肌肉萎缩症。因此,本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制H-PGDS活性和治疗相关疾病的方法。
  • [EN] TRIAZOLE AGONISTS OF THE APJ RECEPTOR<br/>[FR] TRIAZOLES AGONISTES DU RÉCEPTEUR APJ
    申请人:AMGEN INC
    公开号:WO2016187308A1
    公开(公告)日:2016-11-24
    Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures where the definitions of the variables are provided herein.
    公式I和公式II的化合物,其药用盐,上述任何一种的立体异构体,或它们的混合物是APJ受体的激动剂,并可用于治疗心血管和其他疾病。公式I和公式II的化合物具有以下结构,其中变量的定义在此提供。
  • [EN] INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PROTÉINE KRAS G12C ET LEURS UTILISATIONS
    申请人:SHANGHAI ANTENGENE CORPORATION LTD
    公开号:WO2021244603A1
    公开(公告)日:2021-12-09
    Provided are novel compounds useful as inhibitors of the KRAS protein, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical compositions.
    提供了作为KRAS蛋白抑制剂有用的新化合物,以及包含这些化合物的药物组合物和通过给予这些化合物或药物组合物进行治疗的方法。
  • [EN] NOVEL COMPOUNDS FOR MODULATION OF ROR-GAMMA ACTIVITY<br/>[FR] NOUVEAUX COMPOSÉS POUR LA MODULATION DE L'ACTIVITÉ ROR-GAMMA
    申请人:BIOGEN IDEC INC
    公开号:WO2014028669A1
    公开(公告)日:2014-02-20
    The present invention relates to aryl sulfones and related compounds that are modulators of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these modulators, and methods of modulating ROR-gamma receptors using them. Also provided are methods of using aryl sulfones and related compounds as modulators of ROR-gamma to treat ROR-gamma mediated diseases.
    本发明涉及芳基砜和相关化合物,它们是ROR-gamma受体的调节剂。该发明还提供包含这些调节剂的药物组合物,以及使用它们调节ROR-gamma受体的方法。还提供了使用芳基砜和相关化合物作为ROR-gamma调节剂治疗ROR-gamma介导疾病的方法。
查看更多

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯